Objective To investigate the effect of epristeride on 5-alpha-reductase activity and androgen receptor levels in prostate tissue.
Methods Forty patients with benign prostate hyperplasia were randomly divided into the trial group and the control group with 20 in each group. Patients in the trial group were administered oral epristeride and terazosin, while those in the control group were given just terazosin. All patients underwent trans-urethral resection of the prostate after two weeks, and then the 40 samples of prostate were tested immunohistochemically for 5-alpha-reductase activities and androgen receptor levels.
Results The 5-alpha-reductase in prostate tissue was not stained or lightly stained in the trial group, while it was heavily stained in the control group. The androgen receptor in prostate tissue was heavily stained in both groups.
Conclusion Oral epristeride can inhibit the activity of 5-alpha-redutase in prostate tissue, but it has no obvious effect on the androgen receptor level in prostate tissue.
Citation：
GONG Zhiyong,CUI Shu,XIAN Shuyan,DENG Xianzhong,WANG Jizhong. Effect of Epristeride on 5-Alpha-Reductase Activity and Androgen Receptor Level in Prostate Tissue. Chinese Journal of Evidence-Based Medicine, 2008, 08(12): 1047-1049. doi: 10.7507/1672-2531.20080232
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
Ranjan M, Diffley P, Stephen G, et al. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride. Life Sci, 2002, 71(2): 115-126.
|
| 2. |
Johnsonbaugh RE, Cohen BR, McCormack EM, et al. Effect of fourteen days treatment with epristeride, an uncompetitive 5α-reductase inhibitor, on serum and prostatic testosterone and dihydrotestosterone in men with benign prostatic hyperplasia. J Urol, 1993, 149: 423a.
|
| 3. |
Marisa C, Eugene B, Eugenio F, et al. 5α-Reductase inhibitory and antiandrogenic activities of novel steroids in hamster seminal vesicles. Chem Pharm Bull, 2002, 50(11): 1447-1452.
|
| 4. |
Baston E, Salem OI, Hartmann RW, et al. 6-Substituted 3,4-dihydronaphthalene-2-carboxylic acids: synthesis and structure-activity studies in a novel class of human 5-alpha-reductase inhibitors. J Enzyme Inhib Med Chem, 2002, 17(5): 303-320.
|
| 5. |
Qian LH, Wang XL, Tu ZH, et al. Inhibition of regrowth of prostatic glandular cells by epristeride. Acta Pharmacol Sin, 2001, 22(9): 847-850.
|
| 6. |
Bartsch G, Rittmaster RS, Klocker H, et al. Dihydrotestosterone and the concept of 5-alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol, 2002, 19(6): 413-425.
|
| 7. |
Wang LG, Mencher SK, McCarron JP, et al. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review. Oncol Rep, 2004, 11(6): 1325-1329.
|
- 1. Ranjan M, Diffley P, Stephen G, et al. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride. Life Sci, 2002, 71(2): 115-126.
- 2. Johnsonbaugh RE, Cohen BR, McCormack EM, et al. Effect of fourteen days treatment with epristeride, an uncompetitive 5α-reductase inhibitor, on serum and prostatic testosterone and dihydrotestosterone in men with benign prostatic hyperplasia. J Urol, 1993, 149: 423a.
- 3. Marisa C, Eugene B, Eugenio F, et al. 5α-Reductase inhibitory and antiandrogenic activities of novel steroids in hamster seminal vesicles. Chem Pharm Bull, 2002, 50(11): 1447-1452.
- 4. Baston E, Salem OI, Hartmann RW, et al. 6-Substituted 3,4-dihydronaphthalene-2-carboxylic acids: synthesis and structure-activity studies in a novel class of human 5-alpha-reductase inhibitors. J Enzyme Inhib Med Chem, 2002, 17(5): 303-320.
- 5. Qian LH, Wang XL, Tu ZH, et al. Inhibition of regrowth of prostatic glandular cells by epristeride. Acta Pharmacol Sin, 2001, 22(9): 847-850.
- 6. Bartsch G, Rittmaster RS, Klocker H, et al. Dihydrotestosterone and the concept of 5-alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol, 2002, 19(6): 413-425.
- 7. Wang LG, Mencher SK, McCarron JP, et al. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review. Oncol Rep, 2004, 11(6): 1325-1329.
